{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:16:15Z","timestamp":1791818175025,"version":"4.3.4"},"reference-count":29,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Alopecia areata (AA) is an autoimmune disorder that affects the hair follicles, resulting in patchy recurrent hair loss. A large body of evidence has demonstrated the favourable clinical response of the Janus kinase (JAK) inhibitors and biologics, but a lack of comprehensive comparison among these therapies exists in the current literature. This study aimed to compare their efficacy. A systematic review and meta\u2010analysis were performed including randomized trials that report the outcomes of the Severity of Alopecia Tool (SALT)\n                    <jats:sub>50<\/jats:sub>\n                    and\/or the mean change in SALT. These articles were pooled and a network meta\u2010analysis (NAM) was conducted. Based on the surface under the cumulative ranking curve estimates obtained for the mean change in SALT score, baricitinib_4\u2009mg (0.7949656) had the best probability of being the most effective therapy, followed by ritlecitinib_200_50\u2009mg (0.7391906) and ivarmacitinib_4 mg (0.7292594). In contrast, dupilumab, secukinumab, tralokinumab and apremilast were less likely to be effective. Targeting the JAK signalling pathway holds great potential for restoring hair regrowth, albeit the contribution of JAK1, JAK2, JAK3 and TYK2 inhibition to the therapeutic effect on AA is apparently different. Baricitinib_4\u2009mg and ritlecitinib 200_50\u2009mg demonstrated notable efficacy, and both molecules displayed a dose\u2010dependent effect, which is not observed with ivarmacitinib. Further investigations into the specific mechanisms of action of these JAK inhibitors are warranted to elucidate the reasons behind these differences.\n                  <\/jats:p>","DOI":"10.1111\/jdv.19797","type":"journal-article","created":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T01:51:14Z","timestamp":1706320274000},"page":"835-843","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta\u2010analysis"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7869-0206","authenticated-orcid":false,"given":"Husein","family":"Husein\u2010ElAhmed","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology Hospital de Baza  Granada Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria, IBS Granada  Granada Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Husein\u2010ElAhmed","sequence":"additional","affiliation":[{"name":"Huetor\u2010Tajar Health Center Andalusian Health Service  Granada Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"397","article-title":"Epidemiology and burden of alopecia areata: a systematic review","volume":"8","author":"Villasante Fricke AC","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.04.1142"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18810"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom10071002"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13053"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.4536"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.20351"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1195858"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad136"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.09.032"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3160"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950450"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051001"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00917"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.9b00188"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.036"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142205"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.209"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.239723"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24567"},{"issue":"4","key":"e_1_2_9_25_1","first-page":"736","article-title":"JAK\u2010STAT pathway inhibitors in dermatology","volume":"76","author":"Miot HA","year":"2023","journal-title":"An Bras Dermatol"},{"key":"e_1_2_9_26_1","unstructured":"https:\/\/www.pfizer.com\/news\/press\u2010release\/press\u2010release\u2010detail\/fda\u2010approves\u2010pfizers\u2010litfulotm\u2010ritlecitinib\u2010adults\u2010and[Acccessed 2nd July 2023]."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2020.05.006"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15903"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1152513"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.02.063"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T06:36:34Z","timestamp":1714026994000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/jdv.19797"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19797","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,26]]},"assertion":[{"value":"2023-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}